Novo Nordisk A/S (NVO): Price and Financial Metrics


Novo Nordisk A/S (NVO)

Today's Latest Price: $66.86 USD

0.23 (-0.34%)

Updated Aug 13 5:29pm

Add NVO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVO Stock Summary

  • NVO has a higher market value than 98.99% of US stocks; more precisely, its current market capitalization is $158,191,511,000.
  • Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.9% of US equities in our set.
  • In terms of volatility of its share price, NVO is more volatile than only 1.86% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are GSK, AZN, CMI, PHG, and CLRO.
  • NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.
NVO Daily Price Range
NVO 52-Week Price Range

NVO Stock Price Chart Technical Analysis Charts


NVO Price/Volume Stats

Current price $66.86 52-week high $68.96
Prev. close $67.09 52-week low $48.60
Day low $66.57 Volume 811,613
Day high $67.14 Avg. volume 1,697,536
50-day MA $66.01 Dividend yield 1.67%
200-day MA $61.31 Market Cap 157.44B

Novo Nordisk A/S (NVO) Company Bio


Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$66.86$262.07 302%

Below please find a table outlining a discounted cash flow forecast for NVO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novo Nordisk A S ranked in the 74th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 304%. The most interesting components of our discounted cash flow analysis for Novo Nordisk A S ended up being:

  • The company has produced more trailing twelve month cash flow than 99.07% of its sector Healthcare.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 3.74% of the free cash flow producing stocks we're observing.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 58.47% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%294%
1%298%
2%302%
3%306%
4%310%
5%314%

Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See INVA, UHS, ARA, ALXN, and ANTM.





NVO Latest News Stream


Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream


Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

10 Biggest Biotechnology Companies

With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.

Investopedia | July 30, 2020

Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial.

Business Wire | July 21, 2020

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 July 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European.

Yahoo | July 20, 2020

Did Hedge Funds Make The Right Call On Novo Nordisk A/S (NVO)?

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

Yahoo | July 17, 2020

How This Pioneer ESG Fund Still Outperforms 80% of Its Peers

The Trillium ESG Global Equity fund’s thoughtful approach to data and commitment to its principles have paid off, especially lately.

Yahoo | July 16, 2020

Read More 'NVO' Stories Here

NVO Price Returns

1-mo 2.09%
3-mo 4.62%
6-mo 6.43%
1-year 35.02%
3-year 55.51%
5-year 26.39%
YTD 16.67%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%
2015 39.39%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.9486 seconds.